EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast and Their Association With the Clinicopathological Prognostic Paremeters

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05703815

Enrollment

Registered

2023-01-30

Start date

2023-01-31

Completion date

2023-03-31

Last updated

2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Breast Cancer

Keywords

EpCAM, P53 , IDC

Brief summary

Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world. In Egypt, breast cancer represents the 2nd most diagnosed cancer among all population. But among Egyptian females it represents the 1st diagnosed cancer representing 32.4%. The main cause of death in breast cancer patients is tumor metastasis. Although only 5-10% of recently diagnosed breast cancer cases show metastasis to distant sites, but still there is a high risk for metastasis in patients with localized primary tumor following successful surgical management. Epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule. It modifies cadherin mediated cell adhesion and it induces epithelial cell migration and proliferation. Some authors elucidate that EpCAM is involved in metastasis. P53 is a known tumor suppressor gene involved in the control of cell cycle, DNA repair and apoptosis. It's one of the most mutated genes in cancer including breast cancer. Mutant p53 has a big role in tumor progression.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

\- Both incisional and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study. 3\. Complete clinical data.

Exclusion criteria

1. Patients with recurrence of the primary tumor. 2. Patients with a history of preoperative chemotherapy and/or radiotherapy. 3. Insufficient or tiny tissue biopsies

Design outcomes

Primary

Measure	Time frame	Description
Diagnosis of breast cancer	two day after staining sections with Immnnohistochemical markers	Immunohistochemical expression of EpCAM and P53 in IDC of the breast

Contacts

Primary ContactRasha M Abdelkareem, lecturer

rasha_abdelkareem@med.sohag.edu.eg01158408563

Backup ContactRasha M Abdelkreem, lecturer

rasha_abdelkareem@med.sohag.edu.eg01022085207

Outcome results